The Indian Clearing Corporation Limited (ICCL), via BSE Notice No. 20260410-36 dated 10 April 2026, has announced the settlement schedule for the Offer to Buy through the Acquisition Window under Takeover (SEBI Substantial Acquisition of Shares and Takeovers) regulations for Aspira Pathlab & Diagnostics Limited.

Key Points

• Notice issued by ICCL under the Settlement/RMS category for the General segment.
• The circular pertains to the Offer to Buy – Acquisition Window mechanism used in open offers/takeovers.
• Aspira Pathlab & Diagnostics Limited is the target company for this acquisition window activity.
• No attachments are included with this notice; settlement schedule details are contained within the notice itself.

Regulatory Changes

No new regulatory changes are introduced. This notice operates under the existing SEBI (Substantial Acquisition of Shares and Takeovers) Regulations framework, which mandates the use of the stock exchange acquisition window for open offer purchases.

Compliance Requirements

• Trading members and custodians must adhere to the settlement schedule as prescribed by ICCL for the Offer to Buy transactions in Aspira Pathlab & Diagnostics Limited.
• Participants tendering shares must ensure timely submission and settlement as per the notified schedule.
• ICCL will handle the clearing and settlement of all transactions executed through the acquisition window.

Important Dates

• Notice Date: 10 April 2026
• Specific settlement dates (pay-in/pay-out) for the acquisition window would be detailed within the full notice schedule issued by ICCL.

Impact Assessment

This notice has a focused, company-specific impact limited to shareholders and trading members dealing in Aspira Pathlab & Diagnostics Limited shares. Market participants holding or intending to tender shares in the open offer must comply with the settlement timeline. Broader market impact is minimal as this is a routine procedural notice for a single-scrip takeover acquisition window.